Frank Scherpen

Frank Scherpen is a researcher at the University of Groningen with extensive expertise in cancer biology and molecular oncology. His research primarily focuses on signal transduction pathways in various cancer types, particularly acute myeloid leukemia, lung cancer, and medulloblastoma. He has contributed to numerous high-impact publications and datasets that advance our understanding of cancer mechanisms and therapeutic resistance.

His research interests span multiple areas including:

• Signal transduction in cancer cells
• Molecular mechanisms of drug resistance
• Genetic and molecular profiling of cancer subtypes
• Targeted therapies for lung cancer and leukemia
• Developmental pathways in brain tumors

Analysis of his recent publications reveals a strong focus on molecular mechanisms of resistance to targeted therapies in lung cancer, particularly regarding EGFR and ALK inhibitors. His work also explores developmental pathways in medulloblastoma and signal transduction abnormalities in leukemias. The research consistently employs advanced genomic and molecular techniques to identify biomarkers and therapeutic targets.

Dr. Scherpen has contributed to significant datasets related to leukemia research, including studies on IKZF1 deletions in B-cell precursor acute lymphoblastic leukemia and EGFR expression in acute myeloid leukemia. His collaborative approach is evident through numerous co-authorships with researchers across oncology and molecular biology fields.